Physician profile
David J Tate
NPI 1336123504
$3,175.27
in general payments reported to CMS, 2019-2025
39 companies · $952 in 2025
The $952 reported for 2025 was more than what 83% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $43.02 · 2021: $179 · 2022: $187 · 2023: $456 · 2024: $1,187 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,595.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $495.39 | 2021-2025 | Enhertu, Tagrisso, Imfinzi |
| Merck Sharp & Dohme LLC | $282.06 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Reflexion Medical, INC. | $227.97 | 2024 | Reflexion Medical Radiotherapy System |
| Teleflex LLC | $196.99 | 2019-2025 | Barrigel |
| Janssen Biotech, INC. | $169.09 | 2024-2025 | Darzalex, Rybrevant, Talvey |
| Zap Surgical Systems, INC. | $154.05 | 2023 | Zap-X Radiosurgery System, Zap-X Treatment Delivery Software, Zap-X Mv Imager |
| Abbott Laboratories | $146.57 | 2023 | Proclaim |
| Ethicon INC. | $124.16 | 2022 | |
| Pfizer INC. | $116.40 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $108.45 | 2022-2025 | |
| Daiichi Sankyo INC. | $105.65 | 2020-2025 | Enhertu, Datroway |
| Abbvie INC. | $103.34 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $101.95 | 2024-2025 | Libtayo |
| Bayer Healthcare Pharmaceuticals INC. | $97.66 | 2019-2025 | |
| Corcept Therapeutics | $89.09 | 2024 | Korlym |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $55.27 | 2023-2024 | Phesgo, Polivy, Kadcyla |
| Amgen INC. | $53.94 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.53 | 2024-2025 | Fruzaqla, Ninlaro |
| Sumitomo Pharma America, INC. | $45.59 | 2024 | Orgovyx |
| Eisai INC. | $44.98 | 2020-2025 | |
| Myriad Genetic Laboratories, INC. | $42.33 | 2024 | Myrisk |
| Syndax Pharmaceuticals, INC. | $33.77 | 2025 | |
| Taiho Oncology, INC. | $31.59 | 2025 | |
| Foundation Medicine, INC. | $28.90 | 2019 | |
| Incyte Corporation | $28.59 | 2025 | Jakafi |
| Siemens Medical Solutions USA, INC. | $27.92 | 2024 | Varian Ethos Treatment Planning |
| Myovant Sciences INC. | $25.42 | 2021 | |
| Kyowa Kirin, INC. | $24.53 | 2024 | Poteligeo |
| Progenics Pharmaceuticals, INC. | $24.01 | 2022 | |
| Celgene Corporation | $22.87 | 2019 | |
| Invivyd INC | $22.42 | 2025 | Pemgarda |
| Azurity Pharmaceuticals, INC. | $19.95 | 2025 | Danziten |
| Geron Corporation | $19.74 | 2025 | Rytelo |
| Varian Medical Systems, INC. | $19.67 | 2019 | |
| Caris Mpi, INC. | $17.68 | 2025 | Mi Cancer Seek |
| Bard Peripheral Vascular, INC. | $14.75 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.